Spark elaborates on proposed Luxturna value-based pricing model

Spark Therapeutics Inc. (NASDAQ:ONCE) Chief Commercial Officer Ron Philip disclosed additional details on the company's value-based pricing proposal to CMS for Luxturna voretigene neparvovec-rzyl during the BIO CEO and Investor Conference in

Read the full 327 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE